Signant and Propeller partner to improve inhaler adherence with sensor

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Catinsyrup)
(Image: Getty/Catinsyrup)

Related tags Signant Health Propeller Health Asthma Copd eCOA Data collection Digital health

The two companies will combine their digital health services to offer clinical trial participants an inhaler equipped with a sensor to analyze patient adherence.

Signant Health announced that it will connect its TrialMax electronic clinical outcome assessment (eCOA) platform to Propeller Health’s inhaler sensor and linked digital health platform. The combined platform will be aimed towards patients living with asthma and chronic obstructive pulmonary disease (COPD).

According to Signant Health, the linked platforms will lead to better patient adherence to inhaled medications by allowing clients to track medication usage.

The offering is targeted at clinical trial sponsors, clinical research organizations (CROs), and academic institutions.

The ability to follow when patients are using an inhaler would allow those connected to the database to determine when symptoms are triggered, as well as how patients are following their treatment plan.

In addition, it could allow researchers to determine how patients’ use of medication relates to their response to treatment, the company stated.

In a previous interview with Outsourcing-Pharma​, Mike Nolte, CEO of Signant Health, told us how its eCOA platform is beneficial for its clients: “The more we can create enhanced visibility for customers to make good investments and decisions and help them measure the experience in the conduct of research, reversing the lens to view this from a patient perspective, the more we see an untapped area to do exciting new things.”

Bill Byrom, the company’s VP of product strategy and innovation, explained that the Propeller’s sensor allows customers to attain this visibility through ‘frictionless’ data collection.

Propeller’s website states that the sensor works with 90% of inhaled medications available on the US market.

Related news

Show more

Related products

show more

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us

Products

View more

Webinars